-
Bio-Thera Solutions Ltd Strikes Licensing Deal with Gedeon Richter for BAT1706 Biosimilar
•
Guangzhou-based Bio-Thera Solutions Ltd has announced a licensing agreement with Hungary’s Gedeon Richter Plc for BAT1706, its biosimilar version of Roche’s (SWX: RO) Avastin (bevacizumab). Under the agreement, Gedeon Richter will obtain exclusive commercialization rights for the drug in the European Union (EU), the UK, Switzerland, Australia, and other European…
-
Roche Completes Acquisition of LumiraDx’s Point-of-Care Solutions Business
•
Swiss pharmaceutical and diagnostics giant Roche (SWX: ROG, OTCMKTS: RHHBY, SWX: RO) has announced the completion of its acquisition of the point-of-care (POC) solutions business from UK-based diagnostics firm LumiraDx, following all necessary antitrust and regulatory approvals. Initially announced at the end of 2023, the acquisition involved an upfront payment…
-
Roche’s H1’24 Financials Show 5% Growth, Eye Care and Cancer Therapies Drive Sales
•
Roche (SWX: ROG, OTCMKTS: RHHBY, SWX: RO), the Swiss pharmaceutical and diagnostics giant, has reported its financial results for the first half of 2024, with group sales remaining stable in Swiss franc terms. However, on a constant exchange rate basis, sales increased by 5% year-on-year to CHF 29.85 billion (USD…
-
Roche’s Susvimo Implant Cleared for Relaunch in US After Voluntary Recall
•
Roche (SWX: RO), the Swiss pharmaceutical giant, has announced the conclusion of the voluntary recall of its Susvimo (ranibizumab) 100mg/mL intravitreal ocular implant in the U.S. market. The implant, indicated for the treatment of neovascular (wet) age-related macular degeneration (nAMD), has received approval from the U.S. Food and Drug Administration…
-
Roche’s Alecensa Secures NMPA Approval as Adjuvant Therapy for Early-Stage NSCLC
•
Roche (SWX: RO), the Swiss pharmaceutical giant, has announced that it has received an additional indication approval from the National Medical Products Administration (NMPA) for its drug Alecensa (alectinib). This new indication is for use as a post-surgery adjuvant therapy in patients with stage 1B to stage IIIA non-small cell…
-
Roche’s Tiragolumab Misses Primary Endpoints in NSCLC Trial, Study Halted
•
Roche (SWX: ROG; SWX: RO; OTCMKTS: RHHBY), the Swiss pharmaceutical giant, has announced that a Phase II/III clinical trial for its TIGIT-targeted antibody tiragolumab, designed for non-small cell lung cancer (NSCLC), did not outperform Keytruda (pembrolizumab), a PD-1 inhibitor. The trial, known as SKYSCRAPER-06, was evaluating the efficacy of tiragolumab…
-
Roche Extends Long-Standing Partnership with Hitachi High-Tech to Innovate Diagnostic Solutions
•
Roche (SWX: RO), a major Swiss pharmaceutical company, has renewed its 46-year partnership with Japan’s Hitachi High-Tech (TYO: 6501) for an additional 10 years to develop innovative diagnostic solutions. This long-standing collaboration has led to an annual impact of over 21 billion in-vitro diagnostic tests, facilitated by more than 84,000…
-
Roche’s Columvi Meets Overall Survival Endpoint in Diffuse Large B-Cell Lymphoma Trial
•
Roche (SWX: RO), a leading Swiss pharmaceutical company, has announced that a late-stage clinical trial for its bispecific antibody Columvi (glofitamab) has successfully met its primary endpoint of overall survival (OS) in patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL). The trial involved patients who had received…
-
Roche Invests EUR 90 Million in New Gene Therapy Center in Germany
•
Swiss pharmaceutical giant Roche (SWX: RO) has inaugurated a new gene therapy development center in Germany, following an investment of EUR 90 million (USD 97.4 million). The expansive 2,500 square meter facility is designed to specialize in the production of gene vectors for clinical trials across various therapeutic areas, including…
